Trimedyne, Inc. is a manufacturer of lasers and disposable fiber optic delivery devices for use in a variety of surgical applications including, urology, orthopedics, ENT surgery, gynecology, GI surgery, and general surgery. Trimedyne's lasers and proprietary delivery systems are designed to reduce the bleeding and trauma of conventional surgery, reduce or eliminate hospital bed stays and shorten recuperation time.
Cardiodyne, a 90% subsidiary of Trimedyne is developing a heart revascularization laser system for cardiovascular surgeons and cardiologists to treat coronary artery disease, the largest single killer among medical conditions and diseases.
Trimedyne is a publicly traded company, listed on the NASDAQ National Market System under the symbol "TMED."
1980
|
Company Founded |
1982
|
Acquired Fiber Optics Company |
1983
|
IPO ($1.20 per share) |
1987
|
First laser approved for sale by FDA for treating blockages in peripheral (below the waist) arteries
|
1992 |
Holmium laser cleared for sale by FDA for use in arthroscopy
|
1994 |
Holmium laser cleared for sale by FDA for use in urology
|
1995 |
Launched 80 watt Holmium laser - OmniPulse MAX™
|
1996 |
First laser device cleared for sale by FDA for treating enlarged prostates
|
1997 |
OmniTip™ switchable tips cleared for sale by FDA
|
1998 |
Reusable bare fiber cleared for sale by FDA
|
1999 |
Laser Needle cleared by FDA for use in decompression of lumbar ( herniated ) spinal discs
|
2000 |
Joint marketing agreement with Surgical Innovations
& Services ( SIS ) |